Inventor · disambiguated record
Jing Xu
Also filed as: XU JING · XU JING MIN
129 granted patents·48 pending applications·828 citations·filing 2001–2025
99Inventor score
Top patents by PatentIndex Score
177 records- 0198US8642546B2FGF21 mutant fusion polypeptides and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Feb 4, 2014·64 cites·11 claims
- 0298US8410051B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Apr 2, 2013·63 cites·21 claims
- 0398US8361963B2Uses of FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2011·Granted Jan 29, 2013·64 cites·4 claims
- 0498US8034770B2FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2009·Granted Oct 11, 2011·63 cites·15 claims
- 0597US8835385B2FGF21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Sep 16, 2014·48 cites·26 claims
- 0697US8795985B2FGF 21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Aug 5, 2014·48 cites·18 claims
- 0797US8618053B2FGF21 mutants multimers and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Dec 31, 2013·45 cites·18 claims
- 0897US8188040B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Granted May 29, 2012·59 cites·21 claims
- 0996US8067548B2Fusion proteins having mutated immunoglobulin hinge regionWANG HAITAO·Filed 2008·Granted Nov 29, 2011·36 cites·11 claims
- 1096US7625564B2Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2006·Granted Dec 1, 2009·41 cites·34 claims
- 1194US9273106B2FGF mutants with reduced proteolysis and aggregationAMGEN INC·Filed 2013·Granted Mar 1, 2016·9 cites·21 claims
- 1293US12203899B1Sample mounting device for a direct tensile test of rock massINST OF GEOLOGY AND GEOPHYSICS CAS·Filed 2024·Granted Jan 21, 2025·3 cites·10 claims
- 1393US11072640B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2018·Granted Jul 27, 2021·3 cites·12 claims
- 1493US10011642B2Methods of treating of diabetes and obesity using FGF21 mutantsAMGEN INC·Filed 2016·Granted Jul 3, 2018·4 cites·28 claims
- 1592US12152060B2Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2023·Granted Nov 26, 2024·1 cites·6 claims
- 1691US8431132B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoWANG HAITAO·Filed 2009·Granted Apr 30, 2013·13 cites·23 claims
- 1791US8380787B2Federation of master data management systemsIBM·Filed 2011·Granted Feb 19, 2013·18 cites·25 claims
- 1891US7625555B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2007·Granted Dec 1, 2009·13 cites·34 claims
- 1991US2025136653A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2024·Application pending·0 cites
- 2090US10905772B2Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)AMGEN INC·Filed 2018·Granted Feb 2, 2021·6 cites·18 claims
- 2190US2024076333A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2289US11586972B2Tool-specific alerting rules based on abnormal and normal patterns obtained from history logsIBM·Filed 2018·Granted Feb 21, 2023·6 cites·20 claims
- 2389US9288793B2Method and apparatus for device-to-device communication setupWANG JIANG·Filed 2010·Granted Mar 15, 2016·11 cites·20 claims
- 2488US11634467B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2019·Granted Apr 25, 2023·3 cites·9 claims
- 2588US9493530B2FGF21 mutants comprising a mutation at position 98, 171 and/or 180AMGEN INC·Filed 2014·Granted Nov 15, 2016·10 cites·25 claims
- 2686US10585774B2Detection of misbehaving components for large scale distributed systemsIBM·Filed 2017·Granted Mar 10, 2020·7 cites·17 claims
- 2786US9375487B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2013·Granted Jun 28, 2016·5 cites·10 claims
- 2885US9667472B2Migrating virtual assetIBM·Filed 2015·Granted May 30, 2017·4 cites·6 claims
- 2985US8948770B2Cluster head assisted method for converting user terminal from D2D communication to cellular communicationDU JINLING·Filed 2012·Granted Feb 3, 2015·9 cites·6 claims
- 3084US11279742B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2018·Granted Mar 22, 2022·1 cites·20 claims
- 3184US9622132B2Switching between cellular and license-exempt (shared) bandsWANG HAIFENG·Filed 2011·Granted Apr 11, 2017·7 cites·16 claims
- 3284US9095589B2Chirally pure isomers of itraconazole for use as angiogenesis inhibitorsLIU JUN O·Filed 2012·Granted Aug 4, 2015·5 cites·9 claims
- 3384US8425895B2Recombinant human interferon-like proteinsWANG HAITAO·Filed 2007·Granted Apr 23, 2013·4 cites·48 claims
- 3484US7964375B2Polynucleotides encoding human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2009·Granted Jun 21, 2011·4 cites·11 claims
- 3583US8938197B2Base station aided mobile-relay candidate pre-selection and pre-deploymentZHOU BIN·Filed 2010·Granted Jan 20, 2015·7 cites·17 claims
- 3683US8832847B2Coordinating data sharing among applications in mobile devicesANAND RANGACHARI·Filed 2012·Granted Sep 9, 2014·6 cites·17 claims
- 3782US11270226B2Hybrid learning-based ticket classification and responseIBM·Filed 2018·Granted Mar 8, 2022·5 cites·14 claims
- 3881US8984361B2Protocols for multi-hop relay system with centralized schedulingNOKIA SIEMENS NETWORKS OY·Filed 2013·Granted Mar 17, 2015·4 cites·20 claims
- 3981US2023265143A1Recombinant human epo-fc-fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2022·Application pending·0 cites
- 4080US12319723B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2023·Granted Jun 3, 2025·0 cites·9 claims
- 4180US11840558B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 4280US11028398B2Fusion proteins having mutated immunoglobulin hinge regionWANG HAITAO·Filed 2011·Granted Jun 8, 2021·2 cites·25 claims
- 4380US10117949B2Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoWANG HAITAO·Filed 2007·Granted Nov 6, 2018·2 cites·27 claims
- 4480US10067692B2Method and apparatus for backing up and restoring cross-virtual machine applicationIBM·Filed 2014·Granted Sep 4, 2018·6 cites·10 claims
- 4580US9279013B2FGF-21 mutants comprising polyethylene glycol and uses thereofWALKER KENNETH W·Filed 2009·Granted Mar 8, 2016·3 cites·53 claims
- 4680US8984480B2Automating and/or recommending data sharing coordination among applications in mobile devicesANAND RANGACHARI·Filed 2012·Granted Mar 17, 2015·6 cites·22 claims
- 4780US7868151B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·14 claims
- 4880US2025121056A1Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)AMGEN INC·Filed 2024·Application pending·0 cites
- 4979US9234022B2Recombinant human interferon-like proteins and method of treatment using themNOVAGEN HOLDING CORP·Filed 2013·Granted Jan 12, 2016·2 cites·42 claims
- 5078US7867482B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·30 claims
Showing the top 50 of 177 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jing Xu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →